Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (ZURA)
CUSIP: G9TY5A101
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Class A Ordinary Shares, par value $0.0001 per share
- Shares outstanding
- 108,236,654
- Total 13F shares
- 45,725,666
- Share change
- +2,833,079
- Total reported value
- $58,985,346
- Put/Call ratio
- 6000%
- Price per share
- $1.29
- Number of holders
- 74
- Value change
- +$1,915,127
- Number of buys
- 29
- Number of sells
- 39
Quarterly Holders Quick Answers
What is CUSIP G9TY5A101?
CUSIP G9TY5A101 identifies ZURA - Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP G9TY5A101:
Top shareholders of ZURA - Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BARCLAYS PLC |
3/4/5
13F
|
10%+ Owner · Company |
0.07%
from 13F
|
2,340,240
|
$24,349,729 | — | 09 Jan 2023 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
4.5%
|
4,860,939
|
$12,152,348 | — | 31 Dec 2024 | |
| Deep Track Capital, LP |
13F
|
Company |
3%
|
3,283,783
|
$8,209,458 | — | 31 Dec 2024 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
|
Company |
4.9%
from 13D/G
|
3,217,503
|
$8,043,758 | — | 31 Dec 2024 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
2.9%
|
3,170,194
|
$7,925,485 | — | 31 Dec 2024 | |
| PFIZER INC |
13F
13D/G
3/4/5
|
Company · Pfizer Inc. 13-5315170 · 10%+ Owner |
4.6%
from 13D/G
|
2,970,022
|
$7,425,055 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
|
Company |
2.5%
|
2,713,464
|
$6,783,661 | — | 31 Dec 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
2.4%
|
2,633,185
|
$6,582,964 | — | 31 Dec 2024 | |
| BRAIDWELL LP |
13F
|
Company |
2.3%
|
2,472,806
|
$6,182,015 | — | 31 Dec 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2.2%
|
2,413,127
|
$6,032,818 | — | 31 Dec 2024 | |
| ADAR1 Capital Management, LLC |
13F
13D/G
|
Company |
3.2%
from 13D/G
|
2,077,251
|
$5,193,128 | — | 31 Dec 2024 | |
| VR Adviser, LLC |
13F
|
Company |
1.9%
|
2,023,166
|
$5,057,915 | — | 31 Dec 2024 | |
| Allostery Investments LP |
13F
|
Company |
1.4%
|
1,515,126
|
$3,787,815 | — | 31 Dec 2024 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
1.4%
|
1,500,000
|
$3,750,000 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.88%
|
955,426
|
$2,388,996 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.81%
|
879,899
|
$2,199,749 | — | 31 Dec 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.65%
|
701,278
|
$1,753,195 | — | 31 Dec 2024 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.64%
|
690,718
|
$1,726,795 | — | 31 Dec 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.48%
|
520,276
|
$1,300,690 | — | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.47%
|
509,599
|
$1,273,998 | — | 31 Dec 2024 | |
| Michael Howell |
3/4/5
|
Chief Scientific Officer and Head of Translational Science |
—
mixed-class rows
|
529,904
mixed-class rows
|
$1,063,813 | — | 18 Jun 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.37%
|
401,994
|
$1,004,986 | — | 31 Dec 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.28%
|
300,000
|
$750,000 | — | 31 Dec 2024 | |
| Boxer Capital Management, LLC |
13F
|
Company |
0.28%
|
300,000
|
$750,000 | — | 31 Dec 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.27%
|
296,161
|
$740,403 | — | 31 Dec 2024 | |
| Christopher Cabell |
3/4/5
|
CMO & Head of R&D |
—
class O/S missing
|
162,060
|
$648,240 | — | 18 May 2023 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.21%
|
223,335
|
$558,338 | — | 31 Dec 2024 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
0.17%
|
186,943
|
$467,358 | — | 31 Dec 2024 | |
| Caption Management, LLC |
13F
|
Company |
0.16%
|
175,987
|
$439,968 | — | 31 Dec 2024 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.14%
|
148,500
|
$371,250 | — | 31 Dec 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.13%
|
144,083
|
$360,208 | — | 31 Dec 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.12%
|
129,114
|
$322,785 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.11%
|
114,108
|
$285,271 | — | 31 Dec 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.1%
|
106,626
|
$266,565 | — | 31 Dec 2024 | |
| Shay Capital LLC |
13F
|
Company |
0.09%
|
93,119
|
$232,798 | — | 31 Dec 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.08%
|
85,917
|
$214,793 | — | 31 Dec 2024 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.07%
|
80,912
|
$202,280 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0.06%
|
65,292
|
$163,231 | — | 31 Dec 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.05%
|
58,961
|
$147,403 | — | 31 Dec 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.05%
|
57,779
|
$144,448 | — | 31 Dec 2024 | |
| Forefront Analytics, LLC |
13F
|
Company |
0.05%
|
53,734
|
$134,337 | — | 31 Dec 2024 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.04%
|
38,999
|
$113,495 | — | 31 Dec 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.04%
|
41,222
|
$103,055 | — | 31 Dec 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.04%
|
39,566
|
$98,916 | — | 31 Dec 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.03%
|
37,657
|
$94,139 | — | 31 Dec 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.03%
|
37,290
|
$93,225 | — | 31 Dec 2024 | |
| Aristides Capital LLC |
13F
|
Company |
0.03%
|
29,600
|
$74,000 | — | 31 Dec 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.03%
|
28,840
|
$72,100 | — | 31 Dec 2024 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
0.02%
|
25,474
|
$63,685 | — | 31 Dec 2024 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.02%
|
24,675
|
$61,688 | — | 31 Dec 2024 |
Institutional Holders of Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (ZURA) as of Q1 2025
As of 31 Mar 2025,
Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (ZURA) was held by
74 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
45,725,666 shares.
The largest 10 holders included
VR ADVISER, LLC, SUVRETTA CAPITAL MANAGEMENT, LLC, Deep Track Capital, LP, RA CAPITAL MANAGEMENT, L.P., GREAT POINT PARTNERS LLC, Pfizer Inc, ADAR1 Capital Management, LLC, BlackRock, Inc., JPMORGAN CHASE & CO, and BRAIDWELL LP.
This page lists
73
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
87
Q1 2025 holders
74
Holder diff
-13
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.